| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 42,930 | 43,190 | 29.03. | |
| 44,055 | 44,185 | 27.03. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 170,00 | 8 | |||
| 135,00 | 57 | |||
| 60,00 | 15 | |||
| 55,00 | 44 | |||
| 52,20 | 500 | |||
| 51,76 | 50 | |||
| 44,270 | 180 | |||
| 44,265 | 193 | |||
| 44,260 | 1.792 | |||
| 44,255 | 193 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/0qf.htm [/URL] | ||||
| 193 | 44,110 | |||
| 1.972 | 44,105 | |||
| 37 | 36,000 | |||
| 120 | 20,800 | |||
| 300 | 20,000 | |||
| 1.052 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 3.674 | 0,825 | 3.032 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 27.03.2026 | 15:14:15 | 45,500 | 193 |
| 27.03.2026 | 14:32:59 | 46,405 | 100 |
| 27.03.2026 | 14:25:01 | 45,870 | 167 |
| 27.03.2026 | 14:25:01 | 45,840 | 33 |
| 27.03.2026 | 14:25:00 | 46,035 | 80 |
| 27.03.2026 | 14:25:00 | 46,035 | 340 |
| 27.03.2026 | 11:18:26 | 46,430 | 59 |
| 27.03.2026 | 11:18:26 | 46,430 | 37 |
| 27.03.2026 | 11:18:26 | 46,430 | 14 |
| 27.03.2026 | 09:53:42 | 46,395 | 12 |
| 27.03.2026 | 09:04:35 | 46,785 | 15 |
| Tagesumsatz Xetra | -0,660 -1,43 % | 1.312 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MODERNA Aktie jetzt für 0€ handeln | |||||
| Fr | MODERNA INC: Stabilität als strategisches Signal | 8 | Maximilian Berger | ||
| Fr | ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential? | 32 | Zacks | ||
| Mi | Moderna Stock is Soaring. Is It Too Late to Buy? | 22 | The Motley Fool | ||
| Di | Moderna stands as the best performing large-cap healthcare stock YTD | 18 | Seeking Alpha | ||
| 19.03. | Pfizer vs Moderna: Which Pharma Stock Has More Upside? | 49 | The Motley Fool |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| So | BioNTech überrascht: Krebsdaten geben Hoffnung! | börsennews.de | BioNTech treibt den strategischen Wandel hin zu einem Onkologie-Unternehmen voran und erzielt dabei erste vielversprechende klinische Fortschritte, insbesondere im Bereich Lungenkrebs. Gleichzeitig... ► Artikel lesen | |
| Sa | Protagonist Therapeutics: Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology Annual Meeting | ACCESS Newswire | One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasisResults further... ► Artikel lesen | |
| Sa | MoonLake Immunotherapeutics AG: MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting | GlobeNewswire (Europe) | Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated... ► Artikel lesen | |
| Sa | Biogen Inc.: Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity | GlobeNewswire (Europe) | In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clear... ► Artikel lesen | |
| So | Biotech nach der Bereinigung: BioNTech, Newron und Emyria im Fokus nachhaltiger Geschäftsmodelle | Small- & Micro Cap Investment |